...
首页> 外文期刊>Radiation oncology >A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy
【24h】

A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy

机译:一种预测矫正剂术治疗肠杆菌术治疗肠蠕子镜检查和晚期肠杆菌患者晚期矫正剂的前瞻性观察研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Purpose We assessed the value of dose-volumetric parameters predicting rectosigmoid mucosal changes (RMC) and late rectosigmoid complications (LRC). Methods Between January 2004 and February 2006, 77 patients with stage IB-IIIB cervical cancer underwent external beam radiotherapy and computed tomography (CT)-based intracavitary irradiation. Total dose to the rectal point and several dose-volumetric parameters for rectosigmoid colon (D20cc, D15cc, D10cc, D5cc, D2cc, D1cc, and D0.1cc , defined as the minimal doses received by the highest irradiated volumes of 20, 15, 10, 5, 2, 1, and 0.1 cc, respectively), were calculated using the equivalent dose in 2 Gy fractions (α/β?=?3, Gy3). The RMC and LRC were graded by rectosigmoidoscopy and Radiation Therapy Oncology Group criteria every 6 months, respectively. Results Of 77 patients, 27 (35.1%) patients developed RMC?≥?score 3 and 22 (28.6 %) patients developed LRC?≥?grade 2. There was a positive correlation between RMC score and LRC grade (r?=?0.728, p?
机译:目的,我们评估了预测矫直物粘膜变化(RMC)和晚期矫正物并发症(LRC)的剂量 - 体积参数的值。方法2004年1月至2006年2月,77例IB-IIIB宫颈癌宫颈癌患者接受外部梁放射治疗和计算断层扫描(CT),基于内部辐射辐照。直肠点的总剂量和肌肉末端结肠的几种剂量 - 体积参数(D20CC,D15cc,D10cc,D5CC,D2CC,D1CC和D0.1cc,定义为由最高照射的20,15,10的最高辐照容积所接收的最小剂量分别计算5,2,1和0.1cc),使用2 Gy级分中的等效剂量(α/β?=Δ3,gy3)计算。每6个月,RMC和LRC分别被矫肌内窥镜检查和放射治疗肿瘤学群标准分别进行评分。结果77名患者,27例(35.1%)患者开发了RMC?≥?得分3和22(28.6%)患者发育LRC?≥?等级2. RMC得分与LRC等级之间存在正相关(R?= 0.728 ,p?<?0.001)。在多变量分析中,D5CC在剂量 - 体积参数中是RMC风险的重要参数?≥?得分3和LRC?≥?等级2(P?<?0.05)。结论D5cc可能是比其他剂量 - 体积参数更可靠的估计,用于预测RMC的风险?≥?得分3和LRC?≥?2级在基于CT的近距离放射治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号